Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor

Inflammation

Volumn 30, Issue 6, 2007, Pages 224-229

  Stenfeldt, Anna Lena ^a   Karlsson, Jennie ^a   Wennerås, Christine ^a   Bylund, Johan ^a   Fu, Huamei ^a   Dahlgren, Claes ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Boc FLFLF; Boc MLF; Cyclosporin H; Formyl peptide receptors; Inhibitors

Indexed keywords

CYCLOSPORIN H; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; RECEPTOR BLOCKING AGENT; TERT BUTYLOXYCARBONYLMETHIONYLLEUCYLPHENYLALANINE; TERT BUTYLOXYCARBONYLPHENYLALANYLLEUCYLPHENYLALANYLLEUCYLPHENYLALANINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUTROPHIL; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

COMPLEMENT C5A; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NADPH OXIDASE; NEUTROPHIL ACTIVATION; NEUTROPHILS; OLIGOPEPTIDES; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 37349045079     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10753-007-9040-4     Document Type: Article

References (26)

1. Schiffmann, E., B. A. Corcoran, and S. M. Wahl. 1975. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc. Natl. Acad. Sci. USA 72:1059-1062.
2. Miller, A. F., and J. J. Falke. 2004. Chemotaxis receptors and signaling. Adv. Protein Chem. 68:393-444.
3. Ye, R. D., and F. Boulay. 1997. Structure and function of leukocyte chemoattractant receptors. Adv. Pharmacol. 39:221-289.
4. Ronald J U., R.S. 1999. Chemoattractant stimulus-response coupling. In: Inflammation: Basic Priciples and Clinical Correlates, R. S. John I G., ed. Lippincott Williams & Wilkins, Philadelphia 607-626.
5. Le, Y., P. M. Murphy, and J. M. Wang. 2002. Formyl-peptide receptors revisited. Trends. Immunol. 23:541-548.
6. Boulay, F., M. Tardif, L. Brouchon, and P. Vignais. 1990. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem. Biophys. Res. Commun. 168:1103-1109.
7. Ye, R. D., S. L. Cavanagh, O. Quehenberger, E. R. Prossnitz, and C. G. Cochrane. 1992. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem. Biophys. Res. Commun. 184:582-589.
8. Fu, H., C. Dahlgren, and J. Bylund. 2003. Subinhibitory concentrations of the deformylase inhibitor actinonin increase bacterial release of neutrophil-activating peptides: A new approach to antimicrobial chemotherapy. Antimicrob. Agents Chemother. 47:2545-2550.
9. Rabiet, M. J., E. Huet, and F. Boulay. 2005. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol. 35:2486-2495.
10. Freer, R. J., A. R. Day, J. A. Radding, E. Schiffmann, S. Aswanikumar, H. J. Showell, and E. L. Becker. 1980. Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry. 19:2404-2410.
11. Betten, A., C. Dahlgren, S. Hermodsson, and K. Hellstrand. 2003. Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met. Scand. J. Immunol. 58:321-326.
12. Fu, H., L. Bjorkman, P. Janmey, A. Karlsson, J. Karlsson, C. Movitz, and C. Dahlgren. 2004. The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide. BMC Cell Biol. 5:50.
13. Fu, H., J. Karlsson, J. Bylund, C. Movitz, A. Karlsson, and C. Dahlgren. 2006. Ligand recognition and activation of formyl peptide receptors in neutrophils. J. Leukoc. Biol. 79:247-256.
14. Migeotte, I., D. Communi, and M. Parmentier. 2006. Formyl peptide receptors: A promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 17:501-519.
15. Perretti, M., N. Chiang, M. La, I. M. Fierro, S. Marullo, S. J. Getting, E. Solito, and C. N. Serhan. 2002. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8:1296-1302.
16. Babbin, B. A., W. Y. Lee, C. A. Parkos, L. M. Winfree, A. Akyildiz, M. Perretti, and A. Nusrat. 2006. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J. Biol. Chem. 281:19588-19599.
17. Hayhoe, R. P., A. M. Kamal, E. Solito, R. J. Flower, D. Cooper, and M. Perretti. 2006. Annexin 1 and its bioactive peptide inhibit neutrophil- endothelium interactions under flow: Indication of distinct receptor involvement. Blood. 107:2123-2130.
18. Machado, F. S., J. E. Johndrow, L. Esper, A. Dias, A. Bafica, C. N. Serhan, and J. Aliberti. 2006. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12:330-334.
19. Gavins, F. N., J. Dalli, R. J. Flower, D. N. Granger, and M. Perretti. 2007. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation. Faseb J. 21:1751-1758 (Abstract)
20. John, C. D., V. Sahni, D. Mehet, J. F. Morris, H. C. Christian, M. Perretti, R. J. Flower, E. Solito and J. C. Buckingham. 2007. Formyl peptide receptors and the regulation of ACTH secretion: Targets for annexin A1, lipoxins, and bacterial peptides. Faseb J. 21:1037-1046 (Abstract).
21. Boyum, A., D. Lovhaug, L. Tresland and E. M. Nordlie. 1991. Separation of leucocytes: Improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34:697-712.
22. Dahlgren, C.,and A. Karlsson. 1999. Respiratory burst in human neutrophils. J. Immunol. Methods. 232:3-14.
23. Lundqvist, H.and C. Dahlgren. 1996. Isoluminol-enhanced chemiluminescence: A sensitive method to study the release of superoxide anion from human neutrophils. Free Radic. Biol. Med. 20:785-792.
24. Wenzel-Seifert, K., and R. Seifert. 1993. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-l-phenylalanyl-l-leucyl-l-phenylalanyl-l-leucyl-l- phenylalanine and cyclosporins A, B, C, D, and E. J. Immunol. 150:4591-4599.
25. Seifert, R., and K. Wenzel-Seifert. 2003. The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors. Life Sci. 73:2263-2280.
26. Christophe, T., A. Karlsson, C. Dugave, M. J. Rabiet, F. Boulay, and C. Dahlgren. 2001. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276:21585-21593.